
    
      This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to
      evaluate safety and immunogenicity of Ad26.ZEBOV and MVA-BN-Filo at different dose levels,
      administered to healthy adults participants. The study consists of a Screening period of up
      to 6 weeks, vaccinations on Day 1 and Day 57, and a post-vaccination phase until the 6 months
      post-boost visit (Day 237). The participants will be randomized at baseline (on Day 1) in a
      2:2:2:1 ratio to Groups 1, 2, 3 and 4. Safety will be monitored throughout the study.
    
  